Droplet Microfluidic Innovations for Single-Cell Applications
Samplix ApS develops microfluidics technologies for high-throughput, function-first single-cell analysis. Our solutions help researchers study what individual cells actually do — not just which markers they express.
At the core of our technology is the generation of highly uniform microfluidic double-emulsion droplets. These droplets act as isolated microreactors fully compatible with standard flow cytometers and cell sorters, allowing scientists to integrate droplet-based workflows directly into existing laboratory infrastructure without specialized detection systems.
Samplix technologies support a wide range of applications, including single-cell secretion assays, cell–cell interaction studies, functional screening, and analysis of cellular heterogeneity. By combining microfluidics with widely adopted analytical instruments, we enable scalable, accessible, and reproducible single-cell experimentation.
Samplix was founded on the vision that high-throughput cellular screening should be accessible without specialized instrumentation. From the beginning, our goal was to democratize screening throughput by enabling researchers to leverage widely available, state-of-the-art laboratory technologies.
To realize this vision, Samplix focused on microfluidic double-emulsion droplets — a format uniquely compatible with standard flow cytometers and cell sorters. By engineering highly stable and uniform droplets, we enabled researchers to analyse and sort droplet-encapsulated live cells using instruments already established as gold standards in research and clinical laboratories.
This approach allowed scientists to move beyond traditional bulk measurements and perform functional single-cell assays at exceptional throughput, while preserving cell viability for downstream applications.
With the introduction of the Xdrop microfluidic platform, Samplix provided a practical and scalable way to integrate droplet-based workflows into existing experimental pipelines. Today, Samplix technologies support applications in single-cell analysis, functional screening, and cellular heterogeneity research across disciplines worldwide.
CEO
Henrik Pfundheller provides expertise in business strategy, building global commercial teams, and establish competent commercial leadership within the areas of genomics and immunology. He has listed one life science company and has been engaged with Immudex, QIAGEN, Exiqon, RiboTask and Denator.
LI Logo svg original
CCO
Trine Overgaard Østerbye provides expertise in leading commercial operations in life sciences startup companies, including companies working within the areas of immunology other cell functionality space. She has been engaged with BioPorto Diagnostics, Svar Life Sciences, and Kementec Solutions.
Chief Development Officer, Product and Application Development
Peter Mouritzen provides expertise in documenting the many applications of the Xdrop technology and builds relationships with key opinion leaders across the globe. He has listed one life science company and has been engaged with QIAGEN and Exiqon.
VP Intellectual Property Rights
Søren Echwald Morgenthaler provides expertise in patent strategy, freedom to operate analysis and business strategy. He has listed one life sciences company and is or has been engaged with Anapa Biotech, Exiqon and Novo Nordisk.
Chairman & Co-Founder
Michael Obermayer is an experienced board member with extensive knowledge in Business Strategy, and Corporate Development. With previous roles at McKinsey & Co., and Fjord Capital Partners, Michael brings a wealth of global experience and strategic acumen to Samplix ApS.
Board member
Lars Kongsbak brings more than 25 years of leadership experience in the life sciences industry. His scientific background and senior leadership experience in the life sciences sector bring valuable strategic insights to Samplix ApS.
Henrik Christensen, Founder and CEO of Kementec Solutions, and serial entrepreneur, brings extensive expertise in biomedical and life sciences. He also holds key board positions, including Chairman of DiaLab and HC Handel & Invest.
Upcoming meetings, webinars, and industry events
Meet us at these events in the second half of 2026:
The Antibody Series (TAS) 2026 | Évora | Sep 16–18
| Antibody Research and Development, Single-Cell Screening
| Drug Discovery, Screening
| Functional Cell Sorting, Single-Cell Screening | Available on demand after the event
| Protein and Antibody Engineering, Antibody Research
| Cytometry, Functional Cytometry, Cell Therapy
Product releases, partnerships, and company news
October 27, 2026
Samplix today announced a €25 million first closing of a WLan-led financing to support the commercial expansion of Xdrop, its single-cell screening platform for antibody discovery and biotherapeutic development.
The financing comprises €3 million in new capital and €22 million in shareholder convertible-bond conversions. All major shareholders participated in the first closing. The round remains open, with a total financing target of €30 million.
Advancing function-first antibody discovery
Xdrop enables researchers to screen cells based on their biological function, helping identify and recover cells producing antibodies with the desired activity. The platform supports high-throughput screening against challenging targets, including membrane-bound proteins, and complex assay formats such as reporter-based assays.
By linking antibody function to the antibody-secreting cell and its corresponding antibody sequence, Xdrop offers researchers a way to identify promising antibody candidates for further investigation and therapeutic development.
Supporting the next phase of growth
The financing strengthens Samplix’s balance sheet and supports further commercial expansion, deeper partnerships with biopharma and academic organisations, and continued development of the Xdrop platform.
As part of the investment, Dr Werner Lanthaler, founder and managing director of WLan and former CEO of Evotec, will join Samplix’s Board of Directors within the next year.
“We are now in a strong position to further scale our platform, deepen our partnerships with biopharma and academia, and continue pushing the boundaries of what’s possible in single-cell workflows,” said Dr Henrik Pfundheller, CEO of Samplix.
Read the full press release for further details on the financing and the investment from WLan.
See the latest news about product releases, webinars and events, partnerships and more.
